Procter & Gamble Health Ltd

Procter & Gamble Health Ltd announced that its shareholders, at the Annual General Meeting held on September 3, 2026, approved the re-appointment of Mr. S. Madhavan as an Independent Director. This reappointment is effective from November 15, 2026, and will be for a tenure of five years. This decision follows a prior communication dated May 26, 2026, regarding the proposed re-appointment, which was subject to shareholder approval. The company has requested this information be taken on record.

Procter & Gamble Health Ltd has submitted its Business Responsibility & Sustainability Report (BRSR) for the Financial Year ended March 31, 2026. The report, which forms part of the Annual Report, details the company's operations, products, employee statistics, and market presence. Key disclosures include business activities accounting for 100% of turnover, international exports to 5 countries contributing 8.24% to turnover, and a workforce comprising 221 employees and 1279 workers. The report also outlines gender diversity metrics, with women representing 28.57% on the Board of Directors and 33.33% of Key Managerial Personnel. It also touches upon CSR applicability and grievance redressal mechanisms.

Procter & Gamble Health Ltd has announced its 59th Annual General Meeting (AGM) will be held on Thursday, September 3, 2026, at 2:30 p.m. The company has dispatched its Annual Report for the Financial Year 2025-26 and the Notice of AGM to its members in electronic mode on August 12, 2026. Shareholders can register to express views or ask questions by August 27, 2026. The Annual Report includes financial highlights, director's report, sustainability reports, and auditor's reports. The company also provided contact details for investor grievances and registrar services.

Procter & Gamble Health Limited has announced the record date for the purpose of its 59th Annual General Meeting (AGM) and the payment of a final dividend, if approved. The record date is set for Thursday, August 27, 2026. The AGM itself will be held on Thursday, September 3, 2026. Eligible shareholders as of the record date will be considered for the final dividend, with payments expected by September 27, 2026. This announcement updates the previously communicated schedule.

Procter & Gamble Health Ltd announced its unaudited financial results for the quarter ended June 30, 2026. The Board of Directors approved the results during a meeting held today. A limited review report from the statutory auditors, Haribhakti & Co. LLP, was also furnished. The company has prepared its financial statements in accordance with Indian Accounting Standard 34 and other generally accepted accounting principles in India. The review was conducted as per Standard on Review Engagements (SRE) 2410.

Procter & Gamble Health Ltd. announced its first quarter results for the period ended June 30, 2026. The company reported sales of ₹356 crores, marking a 7% increase year-over-year, attributed to strong brand fundamentals, effective retail execution, and positive consumer reception to new products. Profit After Tax (PAT) surged by 45% to ₹96 crores, boosted by sales growth, improved supply chain and go-to-market capabilities, and a one-time gain from the sale of an immovable asset. Excluding this one-time gain, operational PAT grew by 9% to ₹72 crores. The company highlighted its strong start to the financial year, driven by consumer response to innovations and strengthened operational capabilities.

Procter & Gamble Health's standalone revenue from operations (the company has no subsidiary, associate or JV, so standalone is the only basis) grew 7.4% YoY to ₹363.73 Cr for the quarter ended June 30, 2026 (₹338.74 Cr a year ago), though it slipped 1.8% sequentially from ₹370.45 Cr in Q4 FY26. Reported net profit rose 45.3% YoY to ₹96.15 Cr (₹66.18 Cr a year ago) and 1.6% QoQ (₹94.60 Cr), but the headline is inflated by a ₹31.80 Cr exceptional gain on the sale of the company's Worli office premises (sold for ₹33.34 Cr against a carrying value of ₹1.54 Cr). Stripping that out, adjusted PAT was approximately ₹64.35 Cr — down ~2.8% YoY and ~32% QoQ — meaning core profitability actually declined even as revenue grew, the opposite of what the reported number implies. Core operating profit (profit before exceptional items and tax) was ₹97.32 Cr, or 26.8% of revenue — roughly flat against 26.2% a year ago but down sharply from ~36% in the seasonally elevated March-26 quarter. The adjusted net margin nonetheless eased to ~17.7% from 19.3% YoY, pointing to a heavier tax load: total tax of ₹32.97 Cr works out to a 25.5% effective rate on reported PBT, and since the filing does not bifurcate tax between the core business and the one-off property gain, the core tax rate — and hence the adjusted PAT figure — carries some estimation uncertainty. There is no formal management guidance on record from prior quarters, and a web search found none specific to this entity (a same-named but distinct listed peer, P&G Hygiene & Health Care, is often conflated with it), so the print cannot be benchmarked against a stated outlook; the stock is a thinly covered, low-float name with no visible broker consensus for this quarter, so a street beat/miss call is not possible. No separate management press release accompanied the filing. The quarter also carried governance developments — senior management changes announced June 25, 2026 and the AGM date moved to September 3, 2026 — alongside the FY26 final dividend of ₹45/share (record date August 21, 2026) declared earlier in June; none affect this quarter's P&L directly but are relevant context around the print.

Procter & Gamble Health Ltd has announced a revised date for its 59th Annual General Meeting (AGM), now scheduled for Thursday, September 3, 2026. The record date for the purpose of the AGM and the potential payment of a final dividend has been set for Thursday, August 27, 2026. If approved by members at the AGM, the dividend is expected to be paid to eligible shareholders by September 27, 2026. This update supersedes previous communications regarding the AGM schedule.

Procter & Gamble Health Ltd announced its Board of Directors has recommended a final dividend of ₹45 per equity share for the financial year 2025-26. This dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM). The company also detailed the Tax Deducted at Source (TDS) implications for dividend income, outlining applicable rates for resident and non-resident shareholders. Resident shareholders with PAN will face a 10% TDS if their total dividend exceeds ₹10,000, while those without a valid PAN will be subject to 20% TDS. Specific exemptions and documentation requirements are provided for entities like LIC, GIC, Mutual Funds, and government bodies. Non-resident shareholders will be taxed at 20% or the Double Taxation Avoidance Agreement (DTAA) rate, whichever is lower.

Procter & Gamble Health Ltd has announced the closure of its trading window for directors and designated employees. The window will be effective from July 1, 2026, and will remain closed until 48 hours after the publication of the company's unaudited financial results for the quarter ended June 30, 2026. This measure is a standard corporate governance practice to prevent insider trading during sensitive financial reporting periods.